Objective  To observe the efficacy of Zishen Ningxin capsule combined with telmisartan in the treatment of perimenopausal hypertension, and its influence on the patients' blood pressure, biochemical indexes and TCM symptom scores.

Methods  300 patients with perimenopausal hypertension were randomly divided into control group and observation group with 150 patients in each group. The control group was given telmisartan treatment, and the observation group was given Zishen Ningxin capsule on the basis of the control group. The treatment course of both groups was 8 weeks. The dynamic blood pressure and coefficient of variation of blood pressure at 24 h before and after treatment were observed and compared between two groups (24 h systolic blood pressure and coefficient of variation, 24 h diastolic blood pressure and its coefficient of variation), sex hormone levels (serum estradiol, follicle stimulating hormone, testosterone, progesterone), blood lipid levels (triacylglycerol, total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol), renin and hypersensitive C-reactive protein levels, as well as the changes of TCM symptom score were evaluated for the efficacy of the two groups.

Results  After treatment, the 24 h systolic blood pressure and its coefficient of variation, 24 h diastolic blood pressure and its coefficient of variation, the levels of sex hormones, blood lipids, renin and hypersensitive C-reactive protein, as well as TCM symptom scores in two groups were significantly improved (P<0.05), and all indexes in the observation group were better than those in the control group (P<0.05). The total effective rate of observation group was significantly higher than that of control group (P<0.05). There was no significant difference of the incidence of adverse reactions in the two groups (P>0.05).

Conclusion  Zishen Ningxin capsule combined with telmisartan has significant clinical efficacy in the treatment of perimenopausal hypertension, which can effectively reduce blood pressure, relieve symptoms, improve the levels of sex hormones, blood lipids, renin and hypersensitive C-reactive protein.

1.侯帆, 贺桂莲, 张韵, 等. 刘春华防治围绝经期高血压经验[J]. 中医药临床杂志, 2020, 32(6): 1043-1046. [Hou F, He GL, Zhang Y, et al. LIU Chunhua's experience in prevention and treatment of perimenopausal hypertension[J]. Journal of Clinical Chinese Medicine, 2020, 32(6): 1043-1046.] DOI: 10.16448/j.cjtcm.2020. 0614.

2.席爱萍, 李欣, 刘可心, 等. 围绝经期女性baPWV、ABI及血清Hcy、Lp(a)与心血管事件的相关性分析[J].

中国实验诊断学, 2022, 26(6): 799-803. [Xi AP, Li X, Liu KX, et al. Correlation between baPWV, ABI, serum Hcy, Lp(a) and cardiovascular events in perimenopausal women[J]. Chinese Journal of Experimental Diagnostics, 2022, 26(6): 799-803.] DOI: 10.3969/j.issn.1007-4287. 2022.06.003.

3.兰菁, 王菲, 林雪. 围绝经期高血压伴睡眠障碍的中西医治疗研究进展[J]. 新疆中医药, 2020, 38(5): 74-77.[Lan J, Wang F, Lin X. Research progress in the treatment of perimenopausal hypertension with sleep disorders by traditional Chinese and Western medicine[J]. Xinjiang Traditional Chinese Medicine, 2020, 38(5): 74-77.] http://qikan.cqvip.com/Qikan/Article/Detail?id=7103722272.

4.中国高血压防治指南修订委员会, 高血压联盟(中国), 中华医学会心血管病学分会中国医师协会高血压专业委员会, 等.中国高血压防治指南(2018年修订版)[J].

中国心血管杂志, 2019, 24(1): 24-56. DOI: 10.3969/j.issn. 1007-5410.2019.01.002.

5.范星, 兰天飙, 王旭. 贝那普利与缬沙坦治疗慢性肾病蛋白尿及高血压[J]. 药物流行病学杂志, 2008, 17(5): 290-292. [Fan X, Lan TB, Wang X. Therapeutic effect of benazepril combination with valsartan in treatment of chronic kidney patients with proteinuria and hypertension[J]. Chinese Journal of Pharmacoepidemiology, 2008, 17(5): 290-292.] DOI: 10.3969/j.issn.1005-0698. 2008.05.005.

6.谢幸, 孔北华, 段涛, 主编. 妇产科学, 第9版[M]. 北京: 人民卫生出版社, 2018: 353.

7.郑筱萸. 中药新药临床研究指导原则[M]. 北京: 中国医药科技出版社, 2002: 73-76, 388-389.

8.韩泰森, 翟琛琛, 罗震寰, 等. 中国部分地区高血压患者用药依从性变化的影响因素分析[J]. 医学新知, 2021, 31(2): 81-87. [Han TS, Zhai CC, Luo ZH, et al. The influencing factors of changes in medication compliance of hypertensive patients in some areas of China[J]. New Medicine, 2021, 31(2): 81-87.] DOI: 10.12173/j.issn. 1004-5511.2021.02.01.

9.国家中医药管理局. 中医内科病证诊断疗效标准ZY/T001.1-1994[S]. 1994.

10.田玉. 绝经后补充雌激素对女性血脂代谢的影响机制[J]. 实用妇产科杂志, 2018, 34(11): 826-829. [Tian Y. Mechanism of the effect of estrogen supplementation on lipid metabolism in postmenopausal women[J]. Journal of Practical Obstetrics and Gynecology, 2018, 34(11): 826-829.] DOI: CNKI:SUN:SFCZ.0.2018-11-013.

11.杜金玲, 周楠, 宋莹倩, 等. 高血压家族史和血脂异常的交互作用对高血压患病风险的影响[J]. 中华疾病控制杂志, 2022, 26(6): 651-656. [Du JL, Zhou N, Song YQ, et al. Interaction effect of hypertension family history and dyslipidemia on the prevalence of hypertension[J]. Chinese Journal of Disease Control, 2022, 26(6): 651-656.] DOI: 10.16462/j.cnki.zhjbkz.2022.06.006.

12.张仲迎, 高歌, 李莹, 等. 高血压合并高同型半胱氨酸与心脑血管病相关性的研究进展[J]. 中华高血压杂志, 2021, 29(7): 622-628. [Zhang ZY, Gao G, Li Y, et al. Research progress on the relationship between hypertension combined with high homocysteine and cardiovascular and cerebrovascular diseases[J]. Chinese Journal of Hypertension, 2021, 29(7): 622-628.] DOI: 10.16439/j.issn.1673-7245.2021.07.006.

13.孟庆海, 马猛华, 余夕潮, 等. 六味地黄方通过上调肠道雌激素受体改善绝经后ApoE-/-小鼠脂代谢异常研究[J]. 南京中医药大学学报, 2020, 36(5): 661-666, 674.[Meng QH, Ma MH, Yu XC, et al. Liuwei Dihuang Formula alleviates abnormal lipid metabolism by up-regulating intestinal estrogen receptors in postmenopausal ApoE- /-  mice[J]. Journal of Nanjing University of Traditional Chinese Medicine, 2020, 36(5): 661-666, 674.] DOI: 10.14148/j.issn.1672-0482.2020.0661.

14.沈晓静, 张敢娟, 吕奇, 等. 何首乌化学成分及其药理活性的研究进展[J]. 热带亚热带植物学报, 2021, 29(4): 439-450. [Shen XJ, Zhang GJ, Lyu Q, et al. Advances in chemical constituents and pharmacological activities of pleuropterus multiflorus[J]. Journal of Tropical and Subtropical Plants, 2021, 29(4): 439-450.] DOI: 10.11926/jtsb.4304.